TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01241721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Mammography (PEM)
Description: Phase 1 of the study will involve imaging the breast with cancer up to 3 times over 2 hours using one half (1/2) of the standard dose of the radioactive tracer, F18FDG, for PEM imaging. If this reduced dose is equivalent to the standard dose then one quarter (1/4) dose will be tested to find the lowest effective radiation dose of tracer to see breast cancer. Phase 2 of the study will involve imaging of both breasts several times over a shorter duration using the lowest effective dose of tracer identified in the first part of the study. This will allow us to examine the reliability of PEM to identify a second unsuspected abnormality in either breast. Patients will be offered biopsy by ultrasound, MRI or PEM as clinically appropriate of lesions suspected of being cancer prior to final surgical planning.
Study: NCT01522222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous, mechanical ventilatory support
Description: Those in the treatment group will receive ventilation, intermittent positive pressure ventilation, while their heart is arrested. The subjects will have their lungs ventilated six times per minute with a tidal volume equal to 7-10 milliliters per kilogram. This range, when combined with a consistent PEEP of 5cm of water pressure, will allow for the peak inspiratory pressure to be maintained at or below 40cm of water pressure. In addition, the FIO2 will remain consistent at the same level that was needed to maintain the pulse oximetry at 94% as well as the end-tidal CO2 at 35mmHg.
Study: NCT02309346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: Use of Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day or Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Use of Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day or Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
Study: NCT02143804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oncolytic adenovirus expressing GMCSF
Description: Treatment once weekly by intravesical route. Use of DDM to first remove the GAG layer of the bladder and to improve virus transduction. Installation of 100 ml. of CG0070 at 10e12 viral particles for 45 minutes inside bladder.
Study: NCT03730753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus
Description: Programmed intermittent epidural bolus added to patient controlled epidural analgesia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous infusion
Description: Continuous infusion added to patient controlled epidural analgesia
Study: NCT01245556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-908662
Description: Capsules, Oral, escalating doses starting at 25 mg, Q 12 h daily, Continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-908662
Description: Capsules, Oral, escalating doses starting at 25 mg Q 12 h daily for 3 weeks with 3 weeks interval for 4 cycles, then Q12 h daily for 3 weeks every 12 weeks, Continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Vial, IV, escalating doses starting at 3 mg/kg, Once every 3 weeks for 6 weeks, then once every 12 weeks, Continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Vial, IV, escalating doses starting at 3 mg/kg, Once every 6 weeks for 4 cycles, then once every 12 weeks, Continuously
Study: NCT05535725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: application of powdered vancomycin in the surgical wound as prophylaxis against the occurrence of surgical site infection
Description: on the application of powdered vancomycin in the surgical wound as prophylaxis against the occurrence of surgical site infection at La Paix State University Hospital Haiti over 2 years.Both groups benefited from the same preoperative asepsis protocol. One hour before the incision, 1g of intravenous ceftriaxone is administered to the patients, this dose is maintained during the 48 hours postoperative every 12 hours. At discharged the two groups of patients received oral cloxacilin 500mg three times a day for one week. Patients are dressed every 2 days until the surgical wound has healed. Patients are seen in the outpatient clinic at 2, 4, and 6 weeks, then at one year. We selected 215 patients and retained 204.
Study: NCT03846336

Intervention type: OTHER
Group type: OTHER
Intervention: Upper extremity function
Description: Upper extremity function was evaluated with 9-Hole Peg Test (9-HPT). The 9-HPT is a brief, standardized, quantitative test of upper extremity function. It consists of moving nine pegs into one of the nine holes on a peg board, then back into an open box. Both the dominant and non-dominant hands are tested twice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity function
Description: Upper extremity function was evaluated with 9-Hole Peg Test (9-HPT). The 9-HPT is a brief, standardized, quantitative test of upper extremity function. It consists of moving nine pegs into one of the nine holes on a peg board, then back into an open box. Both the dominant and non-dominant hands are tested twice.

Intervention type: OTHER
Group type: OTHER
Intervention: Shoulder position sense
Description: Shoulder position sense was evaluated with a Dualer IQTM digital inclinometer (J-TECH medical, Salt Lake City, UT, USA). The absolute error scores (in degrees) for shoulder abduction and flexion at 30° and 60° was calculated. The upper extremity of the participant was positioned with the arm in the scapular plane for the abduction movement and in the sagittal plane for the flexion movement. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. The measurement was repeated 2 more times for a total of 3 trials for each limb (non-dominant and dominant), with a 30-second rest period separating trials.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder position sense
Description: Shoulder position sense was evaluated with a Dualer IQTM digital inclinometer (J-TECH medical, Salt Lake City, UT, USA). The absolute error scores (in degrees) for shoulder abduction and flexion at 30° and 60° was calculated. The upper extremity of the participant was positioned with the arm in the scapular plane for the abduction movement and in the sagittal plane for the flexion movement. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. The measurement was repeated 2 more times for a total of 3 trials for each limb (non-dominant and dominant), with a 30-second rest period separating trials.
Study: NCT01207414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloperidone
Description: Iloperidone tablets supplied at doses of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to achieve a target dose of 12-24 mg/day for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloperidone
Description: Iloperidone tablets supplied at doses of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to achieve a target dose of 12-24 mg/day for 12 weeks.
Study: NCT01527370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine Live
Description: One approximately 0.65 mL injection subcutaneously on Day 1
Study: NCT03104127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alter G Bionic Leg
Description: Participants are randomized to a 10 week, community-based bionic leg programme. Participants must use the leg for a minimum of 1 hour per day and continue to have active physical therapy sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal therapy (physiotherapy)
Description: Participants are randomized to a normal therapy (physiotherapy) only program. Participants are also advised to undertake 1 hour a day of physical activity and have active physical therapy (physiotherapy) sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal therapy (physiotherapy)
Description: Participants are randomized to a normal therapy (physiotherapy) only program. Participants are also advised to undertake 1 hour a day of physical activity and have active physical therapy (physiotherapy) sessions.
Study: NCT03216772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus PK Morcellator in PneumoLiner
Description: Laparoscopic Supracervical Hysterectomy (LSH) or Total Laparoscopic Hysterectomy (TLH) using Olympus PK Morcellator in PneumoLiner containment device
Study: NCT03130738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7-Day Miconazole Oil (Miconazole 2%)
Description: 7 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14-Day Miconazole Oil (Miconazole 2%)
Description: 14 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 14-Day Placebo - Oil Vehicle
Description: 14 days of 2x per day treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
Study: NCT04298320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 was administered 200mg iv every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN 457
Description: AIN457 was administered 150mg or 300mg ih every 2 weeks
Study: NCT04367727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light emitting diode
Description: Light emitting diode at a wavelength of 890 nm is produced by an array of 60 gallium aluminum arsenide light-emitting diodes located on flexible pads and the near infrared photo energy is delivered in a noninvasive, drug-free manner

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Light emitting diode
Description: Light emitting diode at a wavelength of 890 nm is produced by an array of 60 gallium aluminum arsenide light-emitting diodes located on flexible pads and the near infrared photo energy is delivered in a noninvasive, drug-free manner

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light emitting diode
Description: Light emitting diode at a wavelength of 890 nm is produced by an array of 60 gallium aluminum arsenide light-emitting diodes located on flexible pads and the near infrared photo energy is delivered in a noninvasive, drug-free manner

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Light emitting diode
Description: Light emitting diode at a wavelength of 890 nm is produced by an array of 60 gallium aluminum arsenide light-emitting diodes located on flexible pads and the near infrared photo energy is delivered in a noninvasive, drug-free manner

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light emitting diode
Description: Light emitting diode at a wavelength of 890 nm is produced by an array of 60 gallium aluminum arsenide light-emitting diodes located on flexible pads and the near infrared photo energy is delivered in a noninvasive, drug-free manner

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Light emitting diode
Description: Light emitting diode at a wavelength of 890 nm is produced by an array of 60 gallium aluminum arsenide light-emitting diodes located on flexible pads and the near infrared photo energy is delivered in a noninvasive, drug-free manner
Study: NCT03379181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Patients receive a single dose of 80 mg propranolol p.o.
Study: NCT03493997

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Radiotherapy+IAluril®+Ialuril Soft Gels®
Description: Radiotherapy+IAluril®+Ialuril Soft Gels®

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy only
Description: Radiotherapy only
Study: NCT00910650

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells
Description: After chemotherapy, patients receive up to 1 x 10(9) MART-1 F5 TCR transgenic T cells infused i.v., 1 x 10(7) MART-1 peptide pulsed dendritic cells intradermally, and low dose IL-2 500,000 IU/m2 s.c. twice daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-myeloablative conditioning chemotherapy
Description: Patients receive non-myeloablative conditioning chemotherapy with Cyclophosphamide 60 mg/kg/day x 2 days and Fludarabine 25 mg/m2/day i.v. over 30 minutes for 4 days
Study: NCT00771277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Teams
Description: Use of volunteers organized into teams with a coordinator to provide services to TBI family
Study: NCT00423579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin 10/20 mg
Description: 1 tablet containing 10 mg of ezetimibe and 20 mg of simvastatin per day for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin 40 mg
Description: 1 tablet containing 40 mg of simvastatin per day for 6 weeks
Study: NCT01761877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulindac
Study: NCT03013231

Intervention type: BEHAVIORAL
Intervention: Brief Resilience Scale
Description: 6 months post-op, patients will complete the BRS survey as a method of evaluating resilience.
Study: NCT01411345

Intervention type: RADIATION
Group type: OTHER
Intervention: Standard Salvage Radiation Treatment (SSRT)
Description: A total dose of 68 Gy delivered in 34 fractions to the Clinical Target Volume (CTV), 51 Gy in 34 fractions can be given to the pelvic nodes.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Mapped Tumor Salvage RT (MTSRT)
Description: Dose escalation to the imaging or Dynamic Contrast Enhanced MRI (DCE-MRI)-defined dominant region(s) by dose painting at 2.25 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 68 Gy. The mapped tumor (MT) boost region will receive an absolute dose of 76.5 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 80 Gy in 2.0 Gy fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Mapped Tumor Salvage RT (MTSRT)
Description: Dose escalation to the imaging or Dynamic Contrast Enhanced MRI (DCE-MRI)-defined dominant region(s) by dose painting at 2.25 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 68 Gy. The mapped tumor (MT) boost region will receive an absolute dose of 76.5 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 80 Gy in 2.0 Gy fractions.
Study: NCT03861897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KRP-NI + KM
Description: Non instrumental pleural chest physiotherapy (KRP-NI), 2 sessions a day on weekdays and 1 session a day on weekends and mobilization physiotherapy (KM), 1 session per day except weekend during the hospitalization. The combination of the two physiotherapy is KRP-NI + KM. Afterward, 3 sessions per week, renewable until M3 of non instrumental pleural respiratory physiotherapy. If necessary the doctor can prescribe sessions of mobilization physiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KM
Description: Mobilization physiotherapy (1 session per day except weekend) during the hospitalization. Afterward, if necessary the doctor can prescribe sessions of mobilization physiotherapy(KM).
Study: NCT05708053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg twice
Study: NCT04162288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Training - Shared Decision Making in Prenatal Screening
Description: TThe intervention consisted of an online self-study training program lasting 3 hours which aims to engage SDM in a prenatal screening context. The training was divided into four main modules: 1)SDM, 2)DS prenatal screening, 3)Decision aid and 4)Communication between healthcare professionals and patients. In each module, the targeted learning objectives and the work to be carried out (e.g. readings to be made, video to be viewed, evaluation to be carried out, etc.) are presented. Various teaching methods and medias are used during this training: videos, interviews, narrated capsule, readings, links to scientific articles and complementary websites. Videos are done with experts on SDM, ethics of prenatal testing. A simulation in the end is done to put participants in context of an actual consultation with a pregnant woman and her partner. This training was designed to adapt to the learning pace of the user, is hosted on University Laval platform and needs an identification code to enter.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Online Training - Online Training on Prenatal Screening
Description: The control intervention consisted of an online self-study training program lasting 3 hours which aims to provides knowledge for prenatal screening. The training has four main modules: 1)Context and history of prenatal screening(new), 2)DS prenatal screening(existing), 3)Consent in prenatal screening(new) and 4)Communication between healthcare professionals and patients(existing). In each module, the targeted learning objectives and the work to be carried out are presented. Various teaching methods and medias are used during this training: videos, interviews, narrated capsule, readings, links to scientific articles and complementary websites. Videos are done with experts on SDM, ethics of prenatal testing. For the 2 new modules, narrated capsules and reports have replaced videos of experts. There is no simulation at the end. This training was designed to adapt to the learning pace of the user, is hosted on University Laval platform and needs an identification code to enter.
Study: NCT03162926

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VC-02 Combination Product (aka PEC-Direct)
Description: PEC-01 cells loaded into a Delivery Device
Study: NCT03745014

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Accelerate Pheno
Description: The Accelerate Pheno™ system and PhenoTest™ BC Kit is a fully-integrated in vitro diagnostic system. It is FDA-cleared to perform ID of bacteria and yeast in less than 90 minutes and AST in less than 7 hours, on average, directly from positive blood culture.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard blood culture work up as determined by the site's microbiology lab.
Study: NCT00460161

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: 2 treatments/week for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo/sham acupuncture
Description: 2 treatments/week for 4 weeks
Study: NCT04020549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth, Gratitude, & Positive Activities
Description: Reading and writing activities based on growth (designed to instill the belief that people can change), gratitude (noticing and appreciating good things in life), and behavioral activation (identifying and scheduling positive activities).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Study Skills Control
Description: Reading and writing activities designed to teach evidence-based study strategies.
Study: NCT04030143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Administered as an intramuscular (IM) depot injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Administered as an IM depot injection.
Study: NCT02484248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketotifen
Description: Ketotifen is an anti-histamine approved by the U.S. FDA to prevent and treat itching of the eyes caused by allergies.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablet looks identical to the ketotifen tablet, but does not contain ketotifen.
Study: NCT01782378

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real LED Treatment
Description: PhotoMedex Helmet: 12 Pods, 4.5 x 4.8cm (21.6 cm2); 20 diodes; 830nm; Power Output (PO) 665.3 mW; Power Density (PD)/LED 30.8 mW/cm2; CW; Time/session 28m 10s\*; Dose: Energy Density 26 J/cm2.~MedX Device: 1 Cluster Head/ear, 2 inch diameter (22.48 cm2); 870nm; PO 90 mW; PD/LED 4 mW/cm2; CW; Time/session 4m; Energy Density 4 J/cm2; 2 Vielight Intranasal Devices: Red, 633nm diode; PO 6.5 mW; PD/LED 7.6 mW/cm2; CW; Time/session 25m; Energy Density 11.4 J/cm2 and NIR, 810nm diode; PO 6.5 mW; PD/LED 7.6 mW/cm2; Pulse frequency 10Hz; Duty Cycle 50%; Time/session 25m; Energy Density 11.4 J/cm2 Thor Photomedicine Helmet: 10 Pods, 6cm diameter (28.3 cm2); 35 diodes; Wavelength 850nm; PO 1050 mW; PD/LED 50 mW/cm2; CW; Time/session 23m, 24s; Energy Density 26 J/cm2 2 Placement sets: 1) midline, 6 cluster heads; 2) L\&R side of head 12 cluster heads (14m, 5s, each set); 1) midline, 5 cluster heads; 2) L\&R side of head 10 cluster heads (11m, 42s, each set) CW, Continuous Wave

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Real LED Treatment
Description: PhotoMedex Helmet: 12 Pods, 4.5 x 4.8cm (21.6 cm2); 20 diodes; 830nm; Power Output (PO) 665.3 mW; Power Density (PD)/LED 30.8 mW/cm2; CW; Time/session 28m 10s\*; Dose: Energy Density 26 J/cm2.~MedX Device: 1 Cluster Head/ear, 2 inch diameter (22.48 cm2); 870nm; PO 90 mW; PD/LED 4 mW/cm2; CW; Time/session 4m; Energy Density 4 J/cm2; 2 Vielight Intranasal Devices: Red, 633nm diode; PO 6.5 mW; PD/LED 7.6 mW/cm2; CW; Time/session 25m; Energy Density 11.4 J/cm2 and NIR, 810nm diode; PO 6.5 mW; PD/LED 7.6 mW/cm2; Pulse frequency 10Hz; Duty Cycle 50%; Time/session 25m; Energy Density 11.4 J/cm2 Thor Photomedicine Helmet: 10 Pods, 6cm diameter (28.3 cm2); 35 diodes; Wavelength 850nm; PO 1050 mW; PD/LED 50 mW/cm2; CW; Time/session 23m, 24s; Energy Density 26 J/cm2 2 Placement sets: 1) midline, 6 cluster heads; 2) L\&R side of head 12 cluster heads (14m, 5s, each set); 1) midline, 5 cluster heads; 2) L\&R side of head 10 cluster heads (11m, 42s, each set) CW, Continuous Wave

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham LED Treatment
Description: Intervention for Real and Sham are Identical, but sham has power output of 0, no photons emitted.
Study: NCT02866786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethinyl estradiol and cyproterone acetate
Description: Oral Contraceptive Pill
Study: NCT01062958

Intervention type: OTHER
Intervention: Neevo® (a medical food)

Intervention type: OTHER
Intervention: Prenatal vitamins (≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12)